TouchRESPIRATORY got the opportunity to catch up with Professor Leonard B. Bacharier (Center for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA) around the effects of dupilumab on lung function in the LIBERTY ASTHMA VOYAGE study.
The abstract ‘DUPILUMAB IMPROVES LUNG FUNCTION IN CHILDREN WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA: LIBERTY ASTHMA VOYAGE.’ was presented at CHEST 2021, 17-20 October 2021.
Questions
- Could you give us a brief overview of the type 2 phenotype in asthma? (0:15)
- Why is it important to improve lung function in children with moderate-to-severe asthma? (1:03)
- Can you tell me a little about the LIBERTY ASTHMA VOYAGE study and its findings in terms of exacerbation rate and FEV1? (2:18)
- What were the effects of dupilumab on lung function in the LIBERTY ASTHMA VOYAGE study? (3:49)
- What are the clinical applications of these findings? (4:28)
Disclosures: Dr. Bacharier reports personal fees from GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, Circassia, Elsevier, Kinaset, Vertex.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of CHEST 2021 (Virtual).
